MAPK13 stabilization via m6A mRNA modification limits anticancer efficacy of rapamycin
Journal of Biological Chemistry · 2023
DOI: 10.1016/j.jbc.2023.105175 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2023. Verfasst von Joohwan Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Molecular Genetics, Chao Family Comprehensive Cancer Center, School of Medicine, University of California Irvine, Irvi…. Hauptthemen laut MEDLINE: Sirolimus, RNA, Messenger, Adenosine, RNA Stability. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAAA NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
N6-adenosine methylation (m6A) is the most abundant mRNA modification that controls gene expression through diverse mechanisms. Accordingly, m6A-dependent regulation of oncogenes and tumor suppressors contributes to tumor development. However, the role of m6A-mediated gene regulation upon drug treatment or resistance is poorly understood. Here, we report that m6A modification of mitogen-activated protein kinase 13 (MAPK13) mRNA determines the sensitivity of cancer cells to the mechanistic target of rapamycin complex 1 (mTORC1)-targeting agent rapamycin. mTORC1 induces m6A modification of MAPK13 mRNA at its 3' untranslated region through the methyltransferase-like 3 (METTL3)-METTL14-Wilms' tumor 1-associating protein(WTAP) methyltransferase complex, facilitating its mRNA degradation via an m6A reader protein YTH domain family protein 2. Rapamycin blunts this process and stabilizes MAPK13. On the other hand, genetic or pharmacological inhibition of MAPK13 enhances rapamycin's anticancer effects, which suggests that MAPK13 confers a progrowth signal upon rapamycin treatment, thereby limiting rapamycin efficacy. Together, our data indicate that rapamycin-mediated MAPK13 mRNA stabilization underlies drug resistance, and it should be considered as a promising therapeutic target to sensitize cancer cells to rapamycin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Molecular Genetics, Chao Family Comprehensive Cancer Center, School of Medicine, University of California Irvine, Irvine, California, USA.
- Department of Microbiology and Molecular Genetics, Chao Family Comprehensive Cancer Center, School of Medicine, University of California Irvine, Irvine, California, USA; Department of Biological Chemistry, Chao Family C…
- Department of Biological Chemistry, Chao Family Comprehensive Cancer Center, School of Medicine, University of California Irvine, Irvine, California, USA.
- Department of Biological Chemistry, Chao Family Comprehensive Cancer Center, School of Medicine, University of California Irvine, Irvine, California, USA; School of Biological Sciences, University of California Irvine,…
- Department of Microbiology and Molecular Genetics, Chao Family Comprehensive Cancer Center, School of Medicine, University of California Irvine, Irvine, California, USA. Electronic address: ginalee@uci.edu.
Förderung
- NCI NIH HHS
- NIAAA NIH HHS
- NIGMS NIH HHS
- Mary Kay Ash Foundation
- Comprehensive Cancer Center, University of California, Davis
- National Research Foundation of Korea
- U.S. Department of Defense
- National Institutes of Health
Zitieren
APA
Kim, J., Chun, Y., Ramirez, C. B., Hoffner, L. A., Jung, S., Jang, K. H., Rubtsova, V. I., Jang, C., & Lee, G. (2023). MAPK13 stabilization via m6A mRNA modification limits anticancer efficacy of rapamycin. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2023.105175
Vancouver
Kim J, Chun Y, Ramirez CB, Hoffner LA, Jung S, Jang KH, et al. MAPK13 stabilization via m6A mRNA modification limits anticancer efficacy of rapamycin. Journal of Biological Chemistry. 2023. doi:10.1016/j.jbc.2023.105175
BibTeX
@article{Kim2023,
author = {Kim, Joohwan and Chun, Yujin and Ramirez, Cuauhtemoc B and Hoffner, Lauren A and Jung, Sunhee and Jang, Ki-Hong and Rubtsova, Varvara I and Jang, Cholsoon and Lee, Gina},
title = {MAPK13 stabilization via m6A mRNA modification limits anticancer efficacy of rapamycin},
journal = {Journal of Biological Chemistry},
year = {2023},
doi = {10.1016/j.jbc.2023.105175}
}
EUVIMED